This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub
R

ASCO® 2024 Insights: "CAPTIVATE Study - 5.5-Year Follow-Up Outcomes of Fixed-Duration Ibrutinib + Venetoclax in High-risk CLL/SLL"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Ryan Jacobs
By 2024 ASCO® Annual Meeting Insights Hub FEATURING Ryan Jacobs
154 views
July 8, 2024
0 Comments
Login to view comments. Click here to Login

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

2024 ASCO® Annual Meeting Insights Hub: Hematologic Oncology Videos

06:26
ecancer

Post-Transplant Cyclophosphamide Based GVHD Prophylaxis in Patients …

Feat. M. Al Malki, S. Devine
09:04
ecancer

ASCO® 2024 Insights: "Importance of MRD in Newly Diagnosed Mult…

Feat. X. Leleu
27:49
Insights from 2024 EHA Annual Meeting

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Feat. T. Badar
View All

Related Content

AUTOPLAY
22:29
SOHO Brazil 2024

1L Therapy in CLL: What Are the Best Options?

Feat. J. Burger
35:12
Integrity CE

Clinical Practice Updates in CLL/SLL

Feat. M. Cortese, D. Wallace, A. Niu
12:47
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "Experts Discuss Key Abstracts in CLL"

Feat. S. O'Brien, C. Coombs
24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
17:05
Cleveland Clinic Taussig Cancer Institute

Frontline CLL Learnings From Phase 3 RESONATE-2, iLLUMINATE, and E19…

Feat. A. Winter
03:06
City of Hope

CLL Treatment Sequencing: The Importance of First Choice

Feat. S. Rosen
06:53
UC Irvine Health

Fixed-Duration Treatment in CLL: Current Considerations

Feat. E. Brem
25:47
Massachusetts General Hospital Cancer Center

Practice-Changing Updates in Indolent B-Cell Lymphomas

Feat. J. Soumerai
08:42
City of Hope

Venetoclax vs. BTKis in CLL Treatment

Feat. A. Danilov
06:56
Insights from 2023 ASH Annual Meeting

Efficacy of Ibrutinib Arms Across ALPINE and ELEVATE-RR Trials in R/…

Feat. M. Shadman
06:59
Constantine Tam

R/R CLL: A Matching-Adjusted Indirect Comparison of Zanubrutinib vs.…

08:17
Adam Kittai

Highlights From iwCLL 2023: What's New and Practice Informing i…

19:14
2024 ASCO® Annual Meeting Insights Hub

Experts Discuss Highlights and Key Takeaways in CLL From ASCO® and E…

Feat. K. Rogers, J. Woyach
21:12
SOHO Brazil 2024

3L in CLL: The Best Options in a Patient Double-Refractory to Covale…

Feat. J. Burger
15:17
Nicole Lamanna

Sequencing Therapies in CLL: The Importance of First-Line Treatment …

15:21
5th SOHO Italy Annual Conference

How I Treat CLL at the MD Anderson Cancer Center

Feat. A. Ferrajoli
08:45
Insights from 2023 ASH Annual Meeting

The Best of CLL: Highlights & Key Takeaways

Feat. V. Yazbeck
10:06
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Results of A041702, an Alliance Phase 3 S…

Feat. J. Woyach
22:47
Indy Hematology Review

CLL: Evaluating and Therapeutic Approaches for the Management of the…

Feat. J. Woyach
23:11
Indy Hematology Review

Treatment Considerations for Initial Therapy of CLL

Feat. P. Hillmen